newsfilter
← Latest News
Business Wire·

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the AFFIRM-AL